Clinical Trials Logo

Morphea clinical trials

View clinical trials related to Morphea.

Filter by:

NCT ID: NCT00230373 Withdrawn - Morphea Clinical Trials

Imiquimod 5% Cream in Plaque-type Morphea: A Pilot, Prospective Open-label Study

Start date: November 2005
Phase: Phase 3
Study type: Interventional

Localized scleroderma or morphea is a fibrotic disease, imiquimod induces cytokines which inhibit fibrotic activity . We propose that topical imiquimod 5% cream is efficacious and safe in treating plaque-type morphea. Twenty adults will be enrolled for a pilot study. A screening and baseline clinic visit will be required for each patient enrolled in the study. Each visit will involve completing a medical history, skin examination, digital pictures, histologic examination if the patient consents and an ultrasonographic score. One morphea plaque will be treated with topical imiquimod 5% cream, and another morphea lesion with vehicle cream. Patients will be asked about side effects (local and systemic). Patients will be followed up in the clinic at 3, 6 and 9 months of therapy, and 3 months following end of treatment period (month 12).